Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron to Participate in Two Healthcare Investor Conferences in May
CAMBRIDGE,Mass.--(BUSINESS WIRE)--May 2, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare
View HTML
Toggle Summary Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the U.S. Food and Drug Administration ( FDA ) has granted
View HTML
Toggle Summary Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, May 8, 2018 at 5:00 p.m. EDT to discuss its first quarter 2018 operating and financial results.
View HTML
Toggle Summary Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting
– Oral presentation to highlight preliminary results of ACE-083’s Phase 2 trial in patients with facioscapulohumeral muscular dystrophy – – Part 2 of the ongoing Phase 2 trial in patients with facioscapulohumeral muscular dystrophy has been initiated – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.
View HTML
Toggle Summary Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 26, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that two abstracts on lead product candidate luspatercept will
View HTML
Toggle Summary Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 Trial
- Educational webinar to be held on Wednesday, March 28 th at 8:00 a.m. EDT - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 12, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases,
View HTML
Toggle Summary Acceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & Nerve
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2018-- Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the journal Muscle & Nerve has published the final results
View HTML
Toggle Summary Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results
– Top-line results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept are expected in mid-2018 – – Plans to advance neuromuscular agent ACE-083 into Part 2 of the ongoing Phase 2 trials in facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease – – Expanded pipeline with sotatercept
View HTML
Toggle Summary Acceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 20, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, February 27, 2018 at 5:00 p.m. EST to discuss its fourth quarter and full year 2017 operating and financial results.
View HTML
Toggle Summary Acceleron Announces Appointment of Chief Commercial Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 8, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of commercial industry leader, Sujay Kango as
View HTML